Uncategorized

Why Do Cancer Treatments Severely Reduce the Platelet Count?

Cancer treatments often reduce the number of platelets in the blood.

This is primarily caused by chemotherapy drugs.

Chemotherapy targets rapidly dividing cells, including stem cells.

Cancer treatments that damage bone marrow cells may significantly lower the platelet count.

What is thrombocytopenia?

It is a condition in which the platelet count is below the normal range.

Platelets help in the formation of blood clots.

Without platelets, bleeding may not be controlled.

It may lead to unusual bleeding.

Why does the platelet count decline?

It may decline due to three factors:

  • Reduced platelet production
  • Increased platelet destruction
  • Trapping of platelets in an enlarged spleen

Causes other than chemotherapy:

Other cancer therapies:

Other cancer treatments can also affect the bone marrow.

They may include radiation therapy, targeted therapy, or immunotherapy.

Cancers affecting bone marrow:

Certain cancers may directly affect bone marrow function.

Leukemia or certain solid tumors can spread into the bone marrow.

The unhealthy cancer cells may crowd out healthy cell production in the bone marrow.

Enlarged spleen:

Cancer may cause spleen enlargement.

This may trap platelets.

It reduces the circulation of platelets in the blood.

Immune response:

Certain treatments for cancer or cancer itself may induce an immune response.

The immune system may mistakenly produce antibodies against platelets.

Symptoms of thrombocytopenia:

A severely low platelet count may result in:

  • Easy bruising
  • Unusual bleeding
  • Heavy menstrual flow
  • Red or purple spots on the skin
  • Blood in urine or stool

Complications caused by thrombocytopenia:

Risk of internal bleeding:

Low platelet levels may increase the risk of severe internal bleeding even without an injury.

Uncontrolled external bleeding:

It increases the risk of excessive bleeding during surgery.

Even a minor cut can cause excessive blood loss.

Menstrual periods may involve unusually heavy blood flow.

Anemia:

Uncontrolled bleeding may cause severe blood loss.

It may lead to a severe decline in red blood cell count.

Thrombotic complications:

Certain cancer treatments may cause the formation of tiny blood clots.

This can consume a large number of platelets.

A person can have both a reduced platelet count and blood clots.

Diagnosis of thrombocytopenia:

  • Measuring platelet count through a complete blood count (CBC)
  • Examining platelet size and appearance
  • Other investigations, including bone marrow examination

How to treat thrombocytopenia?

It includes therapies to restore the platelet count.

Platelet restoration therapy is based on several factors:

  • The exact cause of platelet reduction
  • The type of cancer and its treatment
  • Individual patient risks

Platelet transfusion:

It is performed when platelet counts have fallen to critically low levels.

It is also administered if a patient is experiencing active bleeding and severe blood loss.

Thrombopoietin Receptor Agonists (TPO-RAs):

These are targeted drugs that stimulate the bone marrow to produce platelets.

Preventing bleeding risk:

Avoiding activities with a high risk of injury.

Lowering or stopping anticoagulant medicines under medical supervision.

Adjusting cancer treatment:

It includes analyzing treatment effects.

It involves reducing the dose, pausing chemotherapy cycles, or changing the drug regimen.

Why is thrombocytopenia monitoring important during a chemotherapy cycle?

It is a vital step before the start of the next chemotherapy cycle.

It involves regularly measuring platelet counts.

This helps identify any decline early.

If the platelet count is severely low, the chemotherapy cycle may be delayed or paused.

The dose may be reduced.

It helps guide treatment to restore platelets when counts are critically low.

Common cancers that may severely lower the platelet count:

  • Acute myeloid leukemia
  • Acute lymphoblastic leukemia
  • Myelodysplastic syndromes
  • Hodgkin and non-Hodgkin lymphoma
  • Multiple myeloma
  • Metastatic solid tumors

Aprazer Healthcare – Improving access to cancer medicines

As an oncology medicine manufacturer, Aprazer Healthcare believes in supporting cancer treatment through affordable access to anticancer drugs.

We manufacture a comprehensive range of cancer medicines.

Our portfolio includes a wide range of generic anticancer drugs.

With a strong global presence, we are a recognized anticancer drug exporter from India.